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ABSTRACT:
Despite their ubiquitous expression and high conservation during evolution, 
precise cellular functions of vault ribonucleoparticles, mainly built of multiple major 
vault protein (MVP) copies, are still enigmatic. With regard to cancer, vaults were 
shown to be upregulated during drug resistance development as well as malignant 
transformation and progression. Such in a previous study we demonstrated that human 
astrocytic brain tumours including glioblastoma are generally high in vault levels while 
MVP expression in normal brain is comparably low. However a direct contribution to 
the malignant phenotype in general and that of glioblastoma in particular has not 
been established so far. Thus we address the questions whether MVP itself has a 
pro-tumorigenic function in glioblastoma. Based on a large tissue collection, we re-
confirm strong MVP expression in gliomas as compared to healthy brain. Further, 
the impact of MVP on human glioblastoma aggressiveness was analysed by using 
gene transfection, siRNA knock-down and dominant-negative genetic approaches. 
Our results demonstrate that MVP/vaults significantly support migratory and invasive 
competence as well as starvation resistance of glioma cells in vitro and in vivo. The 
enhanced aggressiveness was based on MVP-mediated stabilization of the epidermal 
growth factor receptor (EGFR)/phosphatidyl-inositol-3-kinase (PI3K) signalling axis. 
Consequently, MVP overexpression resulted in enhanced growth and brain invasion 
in human glioblastoma xenograft models. Our study demonstrates, for the first time, 
that vaults have a tumour-promoting potential by stabilizing EGFR/PI3K-mediated 
migration and survival pathways in human glioblastoma. 
INTRODUCTION
Human glioblastoma multiforme (WHO grade IV, 
GBM) represents the most common and aggressive form 
of primary brain tumour in adults with a median survival 
of less than 15 months [1]. This dismal prognosis is based 
on both, the resistance to current therapeutic options [2] 
and the invasion of tumour cells into the adjacent tissue 
making total surgical resection mostly unachievable 
[3]. The successful chemotherapeutic treatment of brain 
tumours is mainly limited by the blood-brain-barrier and 
the expression of ABC-transporter proteins, acting as drug 
efflux pumps [4]. Another protein frequently linked with 
drug resistance is the major vault protein (MVP), also 
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known as lung resistance protein (LRP) [5]. MVP forms 
the outer shell of the vault, a large and highly abundant 
ribonucleoparticle complex [6]. In addition to MVP, vaults 
contain vault poly(ADP-ribose)-polymerase (vPARP), 
telomerase-associated protein (TEP-1) and several small 
untranslated RNAs (vRNA) [7-9]. Multiple in vitro studies 
demonstrated that MVP is almost generally overexpressed 
in drug-resistant human cancer cells selected against 
diverse chemotherapeutic agents [10]. However, the role 
of MVP and vaults in drug resistance is controversially 
discussed [5, 11, 12]. 
Vaults are widely expressed in eukaryotic organisms 
including humans but surprisingly are missing e.g. in flies, 
worms and plants [9]. Due to their hollow-barrel structure 
which can dynamically open and close, vaults were 
suggested to be involved in transport mechanisms [5, 7, 
13]. Consequently, vaults are of interest in nanotechnology 
and are currently developed as natural nano-capsules e.g. 
for drug delivery applications [14]. Furthermore, vaults 
participate in the regulation and fine-tuning of a variety 
of intracellular signal pathways, including mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K) signalling [9]. Additionally, our group has 
identified MVP as an interferon-stimulated gene regulating 
phosphorylation and hence nuclear translocation of STAT1 
[15]. 
In the healthy human organism the highest levels 
of vaults are found in tissues potentially exposed to 
exo- or endotoxins like the epithelia of the lung and the 
gastrointestinal tract as well as in macrophages [16]. 
During malignant transformation or cancer progression 
MVP expression is initiated or upregulated in various 
tumours [9] including gliomas [17]. Nevertheless a 
definite tumour-promoting function of vaults has not been 
conclusively worked out so far.
Previously, our group and others have reported 
constitutive upregulation of vaults in cells and tissues 
of astrocytic brain tumours [17-19]. Consequently, 
we investigated in this study the impact of MVP 
overexpression on growth dynamics and aggressiveness of 
human GBM in vitro and in vivo. Our data assign -for the 
first time- a tumour-promoting function to vault particles 
overexpressed in many cancer types [5].
RESULTS
MVP-(over)expression in human GBM 
Previously we have reported that cell cultures 
derived from an extended panel of patients with GBM 
almost generally overexpress MVP [17]. In the present 
study we re-confirmed strong MVP gene expression in 
GBM surgical specimens and especially cell cultures, 
whereas the healthy cortex, spinal cord and cerebellum 
were comparably low in MVP mRNA (Figure 1A). 
Consistent data regarding MVP mRNA expression 
upregulation in human GBM were derived from diverse 
in silico datasets like https://www.genevestigator.com/
gv/ (data not shown). Immunofluorescence staining of 
MVP revealed a dotted, cytoplasmic distribution pattern 
indicating formation of vault particles in human GBM 
cells (shown representatively in the MVP-positive 
GMB cell line MR-1 in Figure 1B). Out of all patient-
derived primary cultures and cell lines analysed, only 
one GBM cell model, namely H7, almost completely 
lacked MVP. Consequently we establish stable MVP-
overexpressing (H7/MVP) and corresponding empty 
vector control subclones (H7/vc) to analyse the impact 
on GBM cell behaviour. Selection for MVP-positive 
clones was significantly more efficient as compared to 
the vector control already indicating a positive impact of 
MVP expression on H7 clonogenic cell survival (Figure 
1C and D). Comparably to the endogenous MVP, also 
ectopically expressed MVP localized mainly to dotted, 
preferentially cytoplasmic structures (Figure 1E). Vault 
particle formation in H7/MVP cells was also confirmed 
by 1) 100000×g centrifugation leading to complete MVP 
pelleting and 2) accumulation of MVP to the 45% fraction 
in sucrose-gradient centrifugation [10] (Figure 1F). All 
MVP-positive subclones displayed distinctly changed 
spindle-shaped morphology as compared to parental and 
vector control-transfected H7 cells (Figure 1G).
MVP supports the migratory potential of GBM 
cells
Wound-healing assays demonstrated that ectopic 
MVP expression significantly increased cell migration 
at all time-points analysed (Figure 2A). This MVP-
supported migration was even more pronounced in 
transwell-chamber experiments (Figure 2B) were only 
MVP-overexpressing cells were able to cross the pores 
of the filter. Accordingly, videomicroscopy revealed 
a robust migratory activity of H7/MVP cells and only 
minor cell displacements of the vector controls (Figure 
2C; Supplementary Movies 1 and 2). In order to confirm 
that the migratory potential was indeed mediated by 
vaults, siRNA experiments were performed in MVP-
transfected and endogenously MVP-expressing GBM cell 
models. MVP-targeting siRNA reduced MVP expression 
at the mRNA (Supplementary Figure S1A) and protein 
(compare Figure 4C) levels by around 50-60%. Higher 
efficacy was unobtainable owing to the extended half-life 
of MVP assembled into vaults [15]. However, already this 
partial knock-down resulted in a significant reversal of the 
migratory phenotype in MVP-transfected H7 cells (Figure 
2D) while vector control cells remained widely migration-
incompetent (Supplementary Figure S1B). Accordingly, 
MVP siRNA significantly attenuated transwell migration 
in several endogenously MVP-expressing GBM cell 
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models (RAEW representatively in Figure 2D). In order to 
reduce the amount of intact vault particles more efficiently, 
a dominant-negative EGFP-MVP deletion variant 
(dnMVP) was expressed in GBM cells (compare Material 
and Methods; Supplementary Figure S2A). Also dnMVP 
distinctly reduced the migratory potential of MVP-positive 
GBM cell models as compared to the empty vector control 
(Figure 2E) again suggesting an important contribution of 
Figure 1: MVP expression in GBM and establishment of stable MVP-overexpressing H7 sublines. A. MVP mRNA 
expression data in normal (green) and malignant (red) brain tissues as well as tumour cell cultures (yellow), determined by gene expression 
array analyses, were extracted from the BioExpress database (GeneLogic). Sample sizes are given in brackets (Student´s t-test). B. 
Immunofluorescence staining of endogenous MVP (green) in the cytoplasm of MR-1 GBM cells; nuclei (blue) by DAPI; microfilaments 
(red) by TRITC-phalloidin (bar = 10 µm). C. Clone formation of H7 cells transfected with MVP compared to vector control plasmid was 
monitored in three experiments (Student´s t-test). D. MVP expression of MVP-transfected cell clones as compared to parental H7 and 
vector control (vc) cells was analyzed by immunoblot. MR-1 GBM cell extracts served as positive control. E. Exogenously expressed 
MVP (green) was detected by immunofluorescence staining in H7/MVP cells (upper panel) and vector control cells (H7/vc) (lower panel) 
(scale bar = 20 µm). F. Vault particle formation by exogenous and endogenous MVP was confirmed in H7/MVP and A549 cells [5050], 
respectively. Sucrose gradient fractions (left panel) and precipitated proteins after 100000xg centrifugation (right panel), were tested for 
MVP expression by immunoblot. S (supernatant), T (total cell lysate), P100 (100000g pellet). G. Photographs depicting the morphology of 
MVP-overexpressing H7/MVP and the corresponding vector control (H7/vc) cells (scale bar = 100 µm).
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vaults to the migratory potential of GBM cells. 
MVP supports clonogenicity and starvation 
resistance of GBM cells 
MVP overexpression did not alter cell proliferation 
rate at standard culture conditions in 10% foetal calf 
serum (FCS) (data not shown). However, after low density 
seeding, cell proliferation recovered more quickly in MVP-
expressing cells (Figure 3A) corresponding to a reduced 
tendency towards spontaneous cell death induction 
(Figure 3B). Accordingly, only in the MVP-positive 
GBM cell models knockdown of MVP moderately but 
significantly upregulated the spontaneous cell death rate 
(Figure 3C; Supplementary Figure S2B). This suggests 
that vaults support GBM cell survival specifically under 
the stress of low density seeding. Correspondingly, MVP 
overexpression resulted in distinctly enhanced clonogenic 
survival of H7 cells which was significantly reversible 
Figure 2: MVP enhances the migratory potential of human GBM cells. A. Migratory potentials of H7/MVP and H7/vc cells 
were analysed by wound healing assays. Quantitative results (right panel) represent the mean ± SD open area at the indicated time points 
relative to the starting gap set as 1. Three positions of each scratch from two independent experiments were analysed (two-way ANOVA and 
Bonferroni post-test). B. In transwell-migration assays cells at the bottom of filters were stained with crystal violet after the indicated time 
points and counted microscopically in 4 optical fields per filter. Bars represent the means ± SD of three independent experiments performed 
in duplicates (Student´s t-test). C. The spontaneous migratory pattern of H7/MVP and H7/vc cells on culture plastic was analysed by 
videomicroscopy for 24 hours and the average migration distance in the given time interval is shown (two-way ANOVA and Bonferroni 
post-test). D. The impact of siRNA-mediated reduction of ectopic (H7/MVP) and endogenous (RAEW) MVP on transwell filter migration 
was determined 96 hours after transfection (compare B, Student´s t-test). E. U373 cells were infected with an adenovirus encoding 
dominant-negative MVP (dnMVP, MOI 50). The impact on transwell filter migration within 72 hours was determined by measuring the 
absorbance of crystal violet (OD) as described in Material and Methods. D. and E. Bars represent the means ± SD of three independent 
experiments performed in duplicates (Student´s t-test). 
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by MVP siRNA (Figure 3D). In accordance, interference 
with endogenous MVP expression/function by siRNA 
or dnMVP specifically reduced clonogenic growth in all 
tested GBM cell lines (Figure 3E and F).
When the impact of MVP expression on GBM 
cell survival was tested under serum starvation stress, 
the differences became even more distinct. MVP-
overexpressing H7 cells were mostly resistant against 
long-term starvation (75% viable cells after 5 days 
without serum and growth factors), whereas the majority 
(mean = 92%) of MVP-negative vector control cells 
underwent apoptosis in this setting (Figure 3G). Data from 
microscopic evaluation were confirmed by performing 
viability-indicative ATP assays (Figure 3H). 
MVP-mediated upregulation of the PI3K/
AKT/mTOR pathway promotes migration and 
starvation resistance in human GBM cells
Vaults have been shown to interact with several 
intracellular signal cascades including the PI3K/AKT/
mTOR pathway known to exert important roles in survival 
of diverse stress conditions and cell migration [20, 21]. 
Thus, we decided to investigate whether an impact on 
this pathway plays a role in MVP-mediated GBM cell 
survival and migration. Indeed, phosphorylation of the 
PI3K pathway mediators AKT and S6 was upregulated in 
total protein extracts of MVP-overexpressing H7 cells and 
this effect was more pronounced under serum withdrawal 
(Figure 4A). Correspondingly, blockade of MVP by 
Figure 3: MVP supports GBM clonogenic survival and starvation resistance. A. The growth pattern of H7/MVP and H7/vc 
cells seeded at low density (2x104) in 6 well plates was monitored every other day for 2 weeks. The experiment was repeated twice leading 
to comparable results. B. and C. Spontaneous cell death was determined by Hoechst33258/propidium iodide staining at day three after 
seeding (B) or following siRNA-mediated MVP downregulation at day 4 after transfection (C). The percentage of PI-positive cells (dead) 
relative to the total cell number (Hoechst-positive) was calculated. D. Clonogenic survival potential was compared between H7/MVP and 
H7/vc cells 7 days after seeding (left panel) or 8 days after siRNA-mediated MVP down-modulation (middle and right panels). Bar graphs 
represent the cell number counted in 4 defined optical fields per well. E. Clonogenicity was determined in U373 and RAEW cells 8 days 
after siRNA-mediated MVP down-modulation. F. Impact of a dominant-negative MVP variant (dnMVP) on clonogenicity of U373 cells 
was determined 8 days after infection. E and F. The crystal violet absorbance was determined as optical density (OD) at 560nm. B-F. Bar 
graphs represent the means ± SD of three independent experiments (Student´s t-test). G and H. Impact of long-term serum withdrawal (0% 
FCS; 5 days) on cell survival was analysed by Hoechst33258/propidium iodide staining (G) and ATP assay (H, unstarved controls are set 
as 1). Student´s t-tests of data from three independent experiments in duplicates.
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dnMVP or siRNA (Figure 4B and C; respectively) 
reduced phosphorylation of AKT and even stronger of 
S6 in MVP-expressing cell models only. To analyse 
whether this PI3K pathway upregulation is involved in 
the MVP-mediated effects on GBM migration, scratch 
assays with the mTOR and PI3K inhibitors temsirolimus 
and LY294002, respectively, were performed. Both drugs 
completely reversed the higher migratory potential of H7/
MVP cells to levels of the vector control (Figure 4D). 
Correspondingly, the profoundly enhanced survival of 
the MVP-expressing subline under serum withdrawal was 
almost completely reversed already by 1 nM temsirolimus 
(Figure 4E, upper panel). Similarly, clonogenic survival 
was significantly reduced by mTOR blockade specifically 
in the H7 MVP-positive background (Figure 4E, lower 
panel) and all endogenously MVP-expressing GBM cell 
Figure 4: MVP supports migration and starvation resistance of GBM cells mainly via PI3K pathway upregulation. A. 
Impact of serum withdrawal (72 hours) on the phosphorylation status of the indicated proteins was determined by Western blot analysis 
(left panel) and signals evaluated densitometrically (right panel). Data are given as ratios between phosphorylated and total proteins as 
indicated and values normalized to the respective H7/vc controls (dotted line). B. Impact of a dominant-negative MVP variant (dnMVP) on 
PI3K pathway activation was determined 72 hours after infection and compared to empty control or GFP-expressing viruses. Quantification 
(lower panel) was performed as under (A). C. Impact of siRNA-mediated MVP downregulation on MAPK and PI3K signalling under 
standard cell culture conditions was determined 96 hours after transfection. Quantification (right panel) was performed in each case relative 
to the respective siScr control. A-C. Statistical analyses were performed by one-sample t test. D. Effects of PI3K (2.5 µM LY294002) and 
mTOR (75 nM temsirolimus) inhibition on cell migration were determined at the indicated exposure times by wound healing assays (means 
± SD of three experiments performed in duplicates; two-way ANOVA). E. Impacts of the mTOR inhibitor temsirolimus on cell viability at 
the indicated concentrations and FCS conditions (72 hours exposure time; upper panel) and on clonogenic survival (50 nM, 10% FCS, 6 
days exposure; lower panel) were determined (means ± SD of three experiments; Student´s t-test). 
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models tested (RAEW representatively in Supplementary 
Figure S3). 
EGFR signals are involved in MVP-mediated 
stabilization of the PI3K/AKT/S6 signalling axis
As previous studies indicated binding and nuclear 
translocation of the negative PI3K pathway regulator 
phosphatase PTEN by MVP [22-24], we reasoned that 
this MVP function might underlie MVP-mediated PI3K 
pathway upregulation in human GBM cells. Indeed, 
PTEN levels of the MVP-overexpressing H7 subline 
were higher in the nuclear protein extracts but lower in 
100000×g-precipitated membrane-enriched fraction 
as compared to vector control cells (Supplementary 
Figure S4). However when testing several inhibitors 
Figure 5: The EGF/EGFR signalling module is involved in MVP-mediated GBM cell survival, migration and PI3K 
pathway upregulation. A. Impact of EGF stimulation on cell division under serum starvation was analysed as described in Material and 
Methods and values normalized to the respective controls. B. Distance of migration (in µm,) within 24 hours following EGF stimulation 
of serum-starved H7/MVP and H7/vc cells were determined by videomicroscopy. C. The effect of EGFR inhibition (2.5 µM erlotinib) 
on cell migration was determined by wound healing assays. B and C. Means ± SD of three experiments performed in duplicates; two-
way ANOVA. D. Responsiveness of the MAPK and PI3K signal pathways to short-term EGF stimulation (50 ng/ml) of serum-starved 
cells. Quantification in Supplementary Figure S6A. E. EGFR and MVP contents of plasma membrane-enriched (membrane), nuclear 
(nucleus) and post-nuclear (pnuc) protein fractions as indicated. Purity controls compare Supplementary Figure S4. For quantification, band 
intensities were determined, ratios to ß-actin or lamin A/C calculated as appropriate and normalized to the respective values of H7/MVP 
cells. F. Exogenous and endogenous MVP in GBM cells (H7/MVP and RAEW, respectively) was knocked down by siRNA and 96 hours 
later the consequences on EGF responsiveness (15 minutes) analysed by immunoblot. Quantification of the indicated proteins (right panel) 
was performed in each case relatively to the respective siScr controls. Statistical analyses were performed by one-sample t test. 
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against different PI3K signalling cascade molecules, it 
turned out that MVP-overexpressing cells were not only 
hypersensitive against blockade of mTOR and PI3K, 
but also the EGFR inhibitor erlotinib (Supplementary 
Figure S5). This suggests that enhanced PI3K signalling 
in MVP-overexpressing cells might at least in part be 
based on hyperactivation of the EGFR. Accordingly, 
only the MVP-transfected H7 subline significantly 
responded to EGF stimulation by enhanced proliferation 
(Figure 5A). Additionally, the migratory phenotype of 
H7/MVP cells -detectable also under serum starvation- 
was markedly enhanced by EGF while H7/vc cells 
remained unresponsive (Figure 5B). Correspondingly, 
the EGFR inhibitor erlotinib, comparable to LY294002 
and temsirolimus (compare Figure 4D), completely 
reversed the MVP-mediated migratory potential (Figure 
Figure 6: MVP supports GBM xenograft growth and invasiveness. A and B. The impact of MVP status on subcutaneous tumour 
formation dynamics (A) and overall survival (OS) time of mice (B) after inoculation of 1 x 106 H7/MVP and H7/vc cells is depicted. The 
Western blot in (A) demonstrates stable transgenic MVP expression during in vivo propagation. C – H. Impact of MVP on orthotopic GBM 
xenograft growth in the SCID mouse brain was tested by inoculation of 1 x 105 and 1 x 106 H7/MVP and H7/vc cells into the striatum. 
Tumours were obtained 10, 20 and 30 days post infection (dpi). C. Representative photomicrographs of H&E and Ki-67- (immuno)stained 
sections are shown (1 x 106, 30dpi). In D and E the percentage of mitotic and apoptotic figures, respectively, were evaluated on H&E-
stained tissue sections. F. Tumour invasiveness was quantified by evaluation of Ki-67-positive cancer cell islets without junction with the 
primary xenograft mass. G and H. Immunostaining for MVP (G) are opposed to immunohistochemical detection of phosphorylated AKT 
(pAKT) (H). Percentage of pAKT-positive cells is given in I. In case of (D), (E), (F) and (I) at least 6 sections derived from tumours 20 and 
30 dpi (1 x 105 and 1 x 106 cells) were evaluated microscopically (means ± SD; Student´s t-test). Scale bars are in C, G and H = 100 µm, 
10 µm in the insets.
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5C). EGF stimulation of serum-starved cells induced 
hyperactivation of both the MAPK and PI3K pathways in 
the MVP-positive background (Figure 5D, quantification 
in Supplementary Figure S6A). Accordingly, we 
observed a MVP-mediated upregulation of EGFR in both 
membrane-enriched and postnuclear supernatant protein 
fractions of H7 cells (Figure 5E). Furthermore, video 
analysis of EGFP-MVP revealed enhanced translocation 
of vault particles to distinct membrane-subdomains and 
ruffling edges in response to EGF stimulation especially 
under starved conditions (Supplementary Figure S6B, 
Supplementary Movie 3 and 4). In contrast, siRNA-
mediated downregulation of endogenous (RAEW) 
and transfected (H7/MVP) MVP under serum-starved, 
EGF-stimulated conditions resulted in decreased EGFR 
expression and reduced AKT and S6 phosphorylation 
(Figure 5F). Summarizing, this data suggest that MVP 
enhances responsiveness of human GBM cells to the EGF/
EGFR signalling axis by upregulating EGFR levels at the 
GBM cell membrane. 
MVP overexpression in human GBM induces 
increased aggressiveness in vivo
To test the in vivo relevance of the in vitro data, 
H7/MVP and vector control cells were transplanted both 
subcutaneously and orthotopically into SCID mice. At 
the subcutaneous location MVP induced significantly 
enhanced tumour growth of H7 cells and resulted in a 
distinctly reduced survival time of mice (Figure 6A and B). 
Protein extracts of tumours revealed stable overexpression 
of the MVP transgene during in vivo tumour formation 
(Western blot inset in Figure 6A). Accordingly, when 
injected orthotopically into the brain (Figure 6C) the 
number of mitotic cells (Figure 6D) was enhanced in 
histological sections of the MVP-positive cell model. 
Additionally, the number of apoptotic figures was, like 
under in vitro conditions, significantly reduced by MVP 
transfection (Figure 6E). Strikingly, MVP-overexpression 
induced distinct tissue invasion into normal brain with 
fissured margins and multiple Ki-67-positive tumour 
islets invading the surrounding brain parenchyma (Figure 
6C and F). Immunohistochemical staining proved besides 
the stable expression of transfected MVP during xenograft 
growth (Figure 6G) also an enhanced number of cells 
stained positively for phosphorylated AKT (Figure 6H and 
6I). Taken together these data suggest that MVP induces 
pro-survival and pro-migratory phenotypes in GBM cells 
leading to enhanced tumour aggressiveness in vivo. 
DISCUSSION
With regard to malignant progression, enhanced 
levels of MVP and vault particles have been reported in 
several cancer types and were occasionally associated with 
adverse prognosis [5]. Additionally, chemotherapy failure 
and radiation resistance have been frequently linked 
to enhanced MVP/vault expression [5, 25]. However 
a possible direct contribution of vaults to malignant 
phenotypes remains largely unexplored. Here we 
demonstrate that MVP supports aggressiveness of human 
GBM cells and xenografts by fostering an EGFR/PI3K/
AKT pathway-mediated migratory/invasive potential as 
well as starvation resistance.
In a survey of human tissues and organs, brain 
was found to be characterized by comparably low MVP 
expression levels with only the microglia displaying 
clear-cut immunohistochemical staining [16, 26]. Thus, 
in an earlier study, we were surprised to detect an almost 
constitutive and intense overexpression of MVP in 
astrocytic brain tumour-derived cell lines [17]. In the 
present study, we now re-confirm activation of MVP gene 
expression in human gliomas as compared to normal 
brain based on extended expression array data sets. In 
accordance, overexpression of MVP in human glioma 
tissues has also been reported by other groups [18, 19]. 
The molecular mechanisms and signals underlying the 
activation of MVP expression in gliomas are still unknown. 
Interestingly, however, enhanced levels of MVP were 
repeatedly found in epileptic brain areas and considered 
as a possible factor causing failure of treatment with anti-
epileptic drugs [27-29]. Moreover, considerable amounts 
of MVP were also present in explanted primary astrocytes 
suggesting that the induction of MVP expression might 
represent a more general stress-induced protection signal 
of neuroectodermal cells [17]. Accordingly, upregulation 
of MVP was also found as a consequence of neuronal/
spinal injury in several model species including rat [30], 
electric ray [31] and zebrafish [32]. A direct functional 
involvement of MVP in neuroregeneration was proven in 
a spinal cord injury zebrafish model [32]. Together these 
observations implicate a stress/injury-inducible, survival- 
and migration-promoting function of vaults in the central 
nervous system.
With regard to gliomas, our present study suggests 
that such MVP-mediated migration- and survival-
promoting functions are also activated during the 
malignant transformation/progression of astrocytes. 
Concerning cell migration, several previous studies 
reported that at different stages of evolution vaults are 
highly expressed in diverse cells with motile potential 
from Dictyostelium amoeba up to mature human dendritic 
cells, macrophages and the microglia [16, 26, 33, 34]. 
The hypothesis on a promigratory function of vaults, 
has now been proven in our GBM cell models by both 
up- and down-regulation of the migratory GBM cell 
potential following MVP overexpression and knock-
down, respectively. Additionally, we observed distinctly 
enhanced brain invasion induced by MVP over-expression 
in an orthotopic glioblastoma xenograft. Consequently, 
GBM-associated MVP activation might have direct 
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clinical relevance considering that diffuse invasion 
is, besides therapy resistance, the main cause of the 
devastating prognosis of GBM patients [35, 36]. 
A second distinct consequence of MVP 
overexpression was uncovered by culturing glioblastoma 
cells under serum-starved conditions. Both overexpression 
and knock-down experiments indicated a major role of 
MVP in preventing apoptosis induction as a consequence 
of growth factor deficiency. In accordance, MEFs from 
MVP-deficient mice were hypersensitive to serum 
withdrawal reacting with enhanced apoptosis induction 
[37]. Interestingly, also knock-out of the two MVP genes 
present in the slime mold Dictyostelium discoideum 
resulted in growth defects specifically under starvation 
conditions [33]. Together these observations suggest 
an evolutionary conserved role of vaults in starvation 
resistance. Additionally, Rhy et al. reported on enhanced 
MVP expression as a contributor to aging-associated 
apoptosis resistance against diverse stress signals in 
human fibroblasts [38]. These protective functions might 
be hijacked in the malignant tissue where cancer cells are 
constantly threatened by shortage in oxygen and nutrition. 
One important intracellular signalling pathway 
known to be able to mediate both migratory competence 
and starvation resistance is the PI3K/mTOR/AKT cascade 
[20, 21] activated by diverse potentially oncogenic receptor 
tyrosine kinases (RTK) including the EGFR. With regard 
to GBM, inhibition of the PI3K pathway by knock-down 
strategies resulted in decreased proliferation, migration, 
and invasion [39]. Several previous observations have 
suggested that vaults might interfere with the PI3K 
cell survival signal axis. Thus an MVP-mediated, cyto-
protective effect against hyperosmotic stress was found 
to be dependent on enhanced PI3K pathway activation 
in SW620 colon cancer cells [40]. Additionally, the first 
intracellular signalling regulator found to interact with 
MVP was the PI3K antagonist and tumour suppressor 
PTEN [24], frequently deregulated in human GBM 
by gene deletion, mutation, promoter methylation or 
miRNA mediated suppression [41, 42]. Subsequently, two 
studies by the group of C. Eng reported MVP-mediated 
nuclear translocation of PTEN which might sequester 
this phosphatase away from its lipid substrates at the 
cell membrane [22, 23]. In accordance with these data, 
we found enhanced levels of PTEN in nuclear extracts 
but reduced levels in membrane-enriched fractions of 
MVP-transfected GBM cells. These data suggest that 
vaults might support PI3K activation by PTEN inhibition. 
However, small molecule kinase inhibitor studies revealed 
that not only blockade of PI3K and mTOR but also of 
EGFR, one of the major oncogenic RTK molecules in 
human GBM [43], completely reversed the effects of 
MVP on GBM cell migration and starvation resistance. 
Thus we hypothesized that EGFR hyperactivation might 
synergize with PTEN inhibition in MVP-mediated 
PI3K signal stabilization and consequently GBM 
aggressiveness. Accordingly, regulation of MVP tyrosyl-
phosphorylation by SHP-2 was suggested to support 
EGF-mediated MAPK pathway activation but probably 
also IGF-driven PI3K/AKT survival signals in fibroblasts 
[37]. Indeed, we found that MVP has a profound impact 
on EGFR expression levels and EGF-responsiveness of 
our GBM cell models. Interestingly, this seems to be a 
lineage-specific effect since in the case of hepatoma cell 
lines we observed gefitinib resistance as a consequence 
of MVP overexpression [44]. This might rely on the fact 
that alterations in EGFR are pivotal and very frequent in 
primary human GBM but not hepatoma. Accordingly an 
association between MVP expression and the proteomic 
signalling network activated by the oncogenic EGFRvIII 
variant in GBM cells was reported recently [19]. Video 
analysis of GBM cells revealed that the transport of vault 
particles to distinct membrane-subdomains and ruffling 
edges was enhanced in response to EGF stimulation 
especially under growth factor-starved conditions. This 
suggests that MVP might directly interact with EGFR or a 
binding partner leading to enhanced protein stabilization 
or altered receptor recycling rates. These possibilities are 
addressed by on-going projects in our lab. 
Taken together our data demonstrate, to the best 
of our knowledge for the first time, that vault particles 
contribute to cancer aggressiveness. We found that MVP 
expression is almost constitutively activated during 
malignant transformation in tumours of astrocytic 
origin and supports EGFR/PI3K signalling pathway 
activation leading to enhanced starvation resistance 
and migration/invasion potential. A possible quality of 
MVP overexpression as predictive marker for GBM 
responsiveness to EGFR, PI3K or mTOR targeting agents, 
as suggested by our transgenic cell models, needs to be 
addressed using well-characterized patient material from 
controlled clinical studies.
MATERIALS AND METHODS 
Drugs and chemicals
Temsirolimus was obtained from Wyeth 
Pharmaceuticals Inc. Erlotinib was generously supplied 
by Roche and LY294002 was obtained from LC Labs. All 
solutions were freshly prepared before use. All other drugs 
were purchased from Sigma.
Cell lines, primary cell cultures and human tissue
U373 GBM and A549 NSCLC cells were obtained 
from the ATCC and grown in minimal essential medium 
(MEM) (PAA) containing 10% FCS (PAA), 1 mM sodium 
pyruvate and 1% non-essential amino acids and in RPMI-
1640 medium (PAA) with 10% FCS, respectively. RAEW 
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cells, established at the Department of Neurosurgery, 
Wagner-Jauregg Hospital in Linz, were cultured in 
RPMI-1640. Furthermore, MR-1 GBM cells were kindly 
provided by Dr. T. Kurata, Tokyo, Japan and were grown 
in RPMI-1640 with 10% FCS. The H7 GBM cell line 
was established at the Institute of Cancer Research, 
Vienna from a 39 old male patient diagnosed with GBM. 
All cell lines and subclones used were authenticated by 
array-comparative genomic hybridization [45] and DNA 
fingerprinting and periodically checked for Mycoplasma 
contamination (Mycoplasma Stain Kit; Sigma).
Stable MVP expression
Stable MVP-overexpressing H7 cell clones and the 
corresponding vector control cells were established as 
described previously [46].
Silencing of MVP
For transient gene silencing cells were transduced 
with ON-TARGETplus SmartPOOL siRNA for MVP 
or for control siRNA (Dharmacon) as described [44]. 
Oligofectamine (Life Technologies) was used as 
transfection reagent. 
Migration assays
Cell migration was tested by wound-healing or 
transwell-chamber assays. Confluent monolayers were 
wounded using a sterile 200 µl tip and treated with the 
respective kinase inhibitors (erlotinib, LY294002 and 
temsirolimus). Photomicrographs from at least three fixed 
positions of scratches were taken at 0, 24 and 48 hours 
on a Nikon Eclipse inverted microscope. Gap-width was 
determined using Tscratch software [47]. Results were 
calculated as percentage open area relative to the starting 
gaps after 24 and 48 hours. Transwell-chamber assays 
were performed as published [48]. The migratory potential 
was analysed either by counting crystal violet-positive 
cells of at least 4 defined fields at the bottom of each 
filter (Image J software, National Institutes of Health). 
Alternatively, migrated cells were destained using a 2% 
SDS solution and absorbance of free crystal violet was 
measured at 560nm. All experiments were performed in 
duplicates and repeated at least twice. 
Videomicroscopy analysis
For migration analysis [49] 50 000 cells were plated 
in each well of a 24-well plate with complete growth 
medium. After overnight cell attachment the medium 
was changed to CO2-independent medium (Gibco-BRL 
Life Technologies, UK) without FCS but supplemented 
with 4mM glutamine. The culture plate was kept in a 37 
°C custom designed incubator built around an inverted 
phase-contrast microscope (World Precision Instruments). 
Images of 3 neighbouring microscopic fields were taken 
at five-minute intervals for 1 day before and 2 days after 
treatment with 50ng/ml EGF. Images from the phase 
contrast microscope were analysed for migration data 
with a cell-tracking program enabling manual marking of 
individual cells and recording their position parameters 
into data files. The parameter “migrated distance” was 
calculated by averaging for each cell the displacement for 
each time interval up to 24 hrs. For each condition at least 
20 cells were tracked from different fields of view and 
all experiments were repeated twice. Cell proliferation 
index was also assessed on the basis of the videos by 
counting cell divisions within the first 48 hours after EGF 
stimulation.
Protein isolation, cell fractionation and Western 
blot analysis
Total cellular protein extracts were isolated from 
untreated semiconfluent cell cultures grown in T-25 
cm2 flaks. For knock-down experiments proteins were 
extracted 4 days after siRNA transfection or adenoviral 
infection. After evaluation of protein concentrations 
using the Micro BCA protein assay reagent kit (Pierce), 
immunoblots were performed as described [44]. Isolation 
of 100000xg protein fractions and sucrose gradient 
centrifugation were performed as described [10, 50]. Cell 
membranes were isolated as published [51]. For extraction 
of postnuclear supernatant and nuclear protein fractions 
the NE-PER Nuclear and Cytoplasmic Extraction kit 
was used (Thermo Fisher Scientific). The following 
primary antibodies were diluted 1 : 1000 in TBS with 
3% BSA and 0,1% Tween: MVP monoclonal mouse 
clone 42 (Transduction Laboratories), phospho-ERK1/2 
(Thr202/Tyr204), ERK1/2, phospho-S6 ribosomal 
protein (Ser240/244), S6, phospho-AKT (Ser473), AKT, 
PTEN and EGFR were all purchased from Cell Signaling 
Technology. ß-actin AC-15 and lamin A/C antibodies 
were both obtained from Sigma. The immunoreactive 
bands were detected with horseradish peroxidase-labelled 
antibodies from Santa Cruz Biotechnology. For band 
quantification the QuantiScan software (Biosoft) was used.
Immunohistochemistry and immunofluorescence
Consecutive tissue sections from formalin-fixed and 
paraffin-embedded brain specimens were deparaffinised 
and rehydrated. After heating for 10 min in 10mM citrate 
buffer (pH 6.0), the slides were incubated overnight at 4°C 
with LRP-56 (for MVP, 1:20; Santa Cruz Biotechnology) 
and p-AKT (Ser473; 1:25; Cell Signalling Technology) 
antibodies, respectively. To evaluate proliferation, sections 
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were stained with the Ki-67 (clone MiB-1) antibody from 
DAKO (Glostrup, Denmark; 1: 100) for 1 hour at room 
temperature. Binding of primary antibodies was detected 
with the UltraVision LP detection system according to the 
manufacturer’s instructions (Thermo Fisher Scientific), 
followed by incubation with 3,3′-diaminobenzidine and 
counterstaining with haematoxylin. Haematoxylin and 
eosin (H&E) staining were used to localize the tumour 
mass in the brain and to count the number of apoptotic 
and mitotic cells. The percentage of pAKT-positive, 
apoptotic and mitotic cells were evaluated by counting 
at least four visual fields per slide microscopically. With 
regard to invasive potential, the number of Ki-67-positive 
islets without junction with the primary tumour mass of 
at least 6 slides from 2 time points (20 and 30 days after 
orthotopic transplantation) was determined. 
For immunofluorescence cells were grown in 
chamber slides and after attachment fixed with 4% 
formalin/phosphate-buffered saline (PBS) followed by 
permeabilization with 0.5% TritonX/PBS. All further 
procedures were done as described [15]. The following 
primary and secondary antibodies were used: LRP-56 
and PTEN as listed above, (all 1:50 in PBS/1% BSA), 
fluorescein isothiocyanate (FITC)-labelled anti-mouse (F-
1010) or anti-rabbit (F-9887) and tetramethyl rhodamine 
isothiocyanate (TRITC)-labelled anti-mouse (T6528) (all 
1:500; Sigma). Actin filaments were visualized with FITC-
phalloidin staining (1:500; Sigma). Stained cells were 
mounted with DAPI (Vectorshield) and further analysed 
using a confocal laser scanning microscope (Zeiss Invert 
Axio Observer.Z1, Two-channel LSM 700 URGB) 
equipped with LD LCI Plan-Apochromat 25x/0.8 Imm 
Korr DIC M27 and EC Plan-Neofluar 40x/1.3 Oil DIC 
M27 objective lenses. Digital images were taken using the 
Zeiss ZEN (2011) software. 
Cell viability, cell death, and clonogenic assays
For cell viability 3 × 103 cells were seeded into 96-
well plates and 24 hours later cells were exposed to drugs 
as indicated. Activity of anticancer drugs was screened by 
MTT assay (EZ4U, Biomedica). Additionally, cell survival 
was measured 5 days after serum withdrawal by CellTiter-
Glo® Luminescent Cell Viability assay (Promega). Cell 
death rates were determined by simultaneous staining 
with Hoechst33258 and propidium iodide as published 
[52]. For clonogenic assays, cells were seeded (in the 
respective experiments 24 h after transfection or viral 
infection) at a density of 3 × 103 cells per well into 6-well 
plates and monitored for at least 7 days. In drug exposure 
experiments, 24 h after seeding cells were treated with 
the respective drugs for 6 days. Cells were stained with 
crystal violet and either counted using Image J software, 
or quantified by densitometry as described above. 
Subcutaneous and orthotopic xenografts
Six- to 8-week-old female, immunodeficient C.B-
17/IcrHsd-Prkcdscid SCID mice were purchased from 
Harlan and kept in a pathogen-free environment. For 
subcutaneous tumour formation 1 x 106 H7/MVP and 
H7/vc cells were injected into the right flanks of mice, 
respectively. Animals were continually controlled for 
distress development and tumour size was determined 
as described [48]. Orthotopically growing brain tumours 
were generated by injection of 1 x 105 or 1 x 106 H7/
MVP and H7/vc cells into the striatum of mouse brain 
as described earlier [53]. Cell injection was carried out 
in anesthetized animals using Lab Standard Stereotaxic 
Instrument supplied with Quintessential Stereotaxic 
Injector (Stoelting) at constant speed 0.5 µl/min. At 10, 
20 and 30 days after cell injection mice were euthanized 
under anaesthesia by transcardial perfusion using PBS 
and Accustain solution (Sigma). Brains were post-fixed 
by immersion in the Accustain fixative for at least 12 
hours at 4 °C. After paraffin embedding, tissues were 
further analysed. All experiments were performed 
according to the Federation of Laboratory Animal Science 
Association guidelines for the use of experimental animals 
and approved by the institutional ethics committee and 
Austrian government authorities (BMWF-68.205/0064-
II/3b/2011 and BMWF-66.009/0157-II/10b/2008).
Statistical analysis
All data are expressed as mean ± S.D. Statistical 
significance of differences was analysed by using unpaired 
Student´s t-test or two-way ANOVA, as appropriate 
followed by Bonferroni post-tests. Survival analysis was 
performed using Kaplan–Meier curves. A p-value < 0.05 
was considered statistically significant. Throughout the 
study the following classification is used: *, p < 0.05; **, 
p < 0.01 ***, p < 0.001.
Other methods
Information of other methods performed, including 
cloning strategies for MVP, EGFP-MVP and dnMVP, 
quantitative reverse transcription-polymerase chain 
reaction and gene expression analysis are provided as 
Supplementary Material and Methods.
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